Artivion (NYSE:AORT) SVP Jean Holloway Sells 6,394 Shares of Stock

Artivion, Inc. (NYSE:AORT) SVP Jean Holloway sold 6,394 shares of the company’s stock in a transaction that occurred on Monday, November 17th. The stock was sold at an average price of $45.17, for a total transaction of $288,816.98. Following the sale, the senior vice president directly owned 163,408 shares of the company’s stock, valued at approximately $7,381,139.36. This trade represents a 3.77% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

Artivion Price Performance

AORT traded up $0.32 during trading on Tuesday, hitting $45.44. 149,362 shares of the stock traded hands, compared to its average volume of 433,748. The business has a 50 day moving average price of $42.72 and a 200 day moving average price of $36.51. The company has a debt-to-equity ratio of 0.52, a current ratio of 4.78 and a quick ratio of 3.48. Artivion, Inc. has a twelve month low of $21.97 and a twelve month high of $48.04. The company has a market cap of $2.15 billion, a price-to-earnings ratio of -108.26 and a beta of 1.65.

Artivion (NYSE:AORT) last issued its quarterly earnings results on Thursday, November 6th. The company reported $0.16 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.14 by $0.02. Artivion had a positive return on equity of 5.70% and a negative net margin of 4.43%.The company had revenue of $113.39 million for the quarter, compared to analyst estimates of $110.71 million. The company’s revenue was up 18.9% on a year-over-year basis. Artivion has set its FY 2025 guidance at EPS. Equities research analysts forecast that Artivion, Inc. will post 0.37 earnings per share for the current fiscal year.

Institutional Trading of Artivion

A number of hedge funds and other institutional investors have recently bought and sold shares of AORT. New York State Common Retirement Fund lifted its stake in shares of Artivion by 104.2% in the first quarter. New York State Common Retirement Fund now owns 83,754 shares of the company’s stock valued at $2,059,000 after buying an additional 42,737 shares in the last quarter. Universal Beteiligungs und Servicegesellschaft mbH purchased a new position in shares of Artivion during the first quarter valued at approximately $3,162,000. MCF Advisors LLC raised its position in Artivion by 109.3% in the 1st quarter. MCF Advisors LLC now owns 1,176 shares of the company’s stock valued at $29,000 after buying an additional 614 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of Artivion by 18.9% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 14,358 shares of the company’s stock valued at $353,000 after purchasing an additional 2,285 shares during the last quarter. Finally, Thornburg Investment Management Inc. bought a new position in shares of Artivion during the first quarter valued at about $3,261,000. Institutional investors own 86.37% of the company’s stock.

Wall Street Analyst Weigh In

AORT has been the subject of a number of research analyst reports. Canaccord Genuity Group upped their price objective on shares of Artivion from $50.00 to $51.00 and gave the stock a “buy” rating in a research report on Friday, November 7th. Stifel Nicolaus boosted their price objective on Artivion from $40.00 to $46.00 and gave the stock a “buy” rating in a research report on Monday, September 29th. Citigroup reissued an “outperform” rating on shares of Artivion in a research note on Friday, October 10th. Needham & Company LLC upped their price objective on Artivion from $50.00 to $58.00 and gave the company a “buy” rating in a research note on Friday, November 7th. Finally, Oppenheimer restated an “outperform” rating and issued a $50.00 price objective on shares of Artivion in a report on Friday, November 7th. Seven equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $49.11.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.